Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells

European Journal of Nutrition

Volumn 53, Issue 3, 2014, Pages 853-864

  González Sarrías, Antonio ^a   Giménez Bastida, Juan Antonio ^a   Núñez Sánchez, María Ángeles ^a   Larrosa, Mar ^a   García Conesa, María Teresa ^a   Tomás Barberán, Francisco A ^a   Espín, Juan Carlos ^a  

^a Research Group on Quality   (Spain)

Author keywords

Cell cycle; Colon cancer; Ellagic acid; Glucuronide; Phase II metabolism; Urolithins

Indexed keywords

ABC TRANSPORTER; AGLYCONE; ANTINEOPLASTIC AGENT; GLUCURONIDE; UNCLASSIFIED DRUG; UROLITHIN A; UROLITHIN B; UROLITHIN C; UROLITHIN D; 3,8-DIHYDROXY-6H-DIBENZO(B,D)PYRAN-6-ONE; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTINEOPLASTIC ANTIBIOTIC; COUMARIN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; TANNIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MTT ASSAY; TANDEM MASS SPECTROMETRY; TRYPAN BLUE ASSAY; ANTAGONISTS AND INHIBITORS; CELL CYCLE G2 PHASE; CELL SURVIVAL; CHEMISTRY; COLON; COLONIC NEOPLASMS; COMPARATIVE STUDY; DRUG DETOXIFICATION; DRUG EFFECTS; DRUG RESISTANCE; INTESTINE MUCOSA; KINETICS; METABOLISM; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLON; COLONIC NEOPLASMS; COUMARINS; DRUG RESISTANCE, NEOPLASM; G2 PHASE; GLUCURONIDES; HUMANS; HYDROLYZABLE TANNINS; INTESTINAL MUCOSA; KINETICS; MEMBRANE TRANSPORT MODULATORS; METABOLIC DETOXICATION, PHASE II; S PHASE;

EID: 84903906709     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-013-0589-4     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ (2006) Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 120:451-458
3. Rudolf E, Andelová H, Cervinka M (2007) Polyphenolic compounds in chemoprevention of colon cancer-targets and signalling pathways. Anticancer Agents Med Chem 7:559-575
4. Pan MH, Lai CS, Wu JC, Ho CT (2011) Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compounds. Mol Nutr Food Res 55:32-45
5. Clifford MN, Scalbert A (2000) Ellagitannins-nature, occurrence and dietary burden. J Sci Food Agric 80:118-125
6. Cerdá B, Periago PM, Espín JC, Tomás-Barberán FA (2005) Identification of urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds. J Agric Food Chem 53:5571-5576
7. Larrosa M, García-Conesa MT, Espín JC, Tomás- Barberán FA (2010) Ellagitannins, ellagic acid and vascular health. Mol Asp Med 31:513-539
8. Espín JC, González-Barrio R, Cerdá B, López-Bote C, Rey AI, Tomás-Barberán FA (2007) Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 55:10476-10485
9. González-Sarrías A, Azorín-Ortuño M, Yáñez-Gascón MJ, Tomás-Barberán FA, García-Conesa MT, Espín JC (2009) Dissimilar in vitro and in vivo effects of ellagic acid and its microbiota-derived metabolites, urolithins, on the cytochrome P450 1A1. J Agric Food Chem 57:5623-5632
10. González-Barrio R, Truchado P, Ito H, Espín JC, Tomás-Barberán FA (2011) UV and MS identification of urolithins and nasutins, the bioavailable metabolites of ellagitannins and ellagic acid in different mammals. J Agric Food Chem 59:1152-1162
11. González-Sarrías A, Giménez-Bastida JA, García-Conesa MT, Gómez-Sánchez MB, García-Talavera NV, Gil-Izquierdo A, Sánchez-Alvarez C, Fontana-Compiano LO, Morga-Egea JP, Pastor-Quirante FA, Martínez-Díaz F, Tomás- Barberán FA, Espín JC (2010) Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol Nutr Food Res 54:311-322
12. Truchado P, Larrosa M, García-Conesa MT, Cerdá B, Vidal-Guevara ML, Tomás-Barberán FA, Espín JC (2012) Strawberry processing does not affect the production and urinary excretion of urolithins, ellagic acid metabolites, in humans. J Agric Food Chem 60:5749-5754
13. Cerdá B, Espín JC, Parra S, Martínez P, Tomás-Barberán FA (2004) The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivates by the colonic microflora of healthy humans. Eur J Nutr 43:205-220
14. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D (2007) Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 55:7732-7737
15. González-Sarrías A, Espín JC, Tomás- Barberán FA, García-Conesa MT (2009) Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins. Mol Nutr Food Res 53:686-698
16. Sharma M, Li L, Celver J, Killian C, Kovoor A, Seeram NP (2010) Effects of fruit ellagitannin extracts, ellagic acid, and their colonic metabolite, urolithin A, on Wnt signaling. J Agric Food Chem 58:3965-3969
17. Kasimsetty SG, Bialonska D, Reddy MK, Ma G, Khan SI, Ferreira D (2010) Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J Agric Food Chem 58:2180-2187
18. Larrosa M, González-Sarrías A, Yáñez- Gascón MJ, Selma MV, Azorín-Ortuño M, Toti S, Tomás-Barberán F, Dolara P, Espín JC (2010) Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem 21:717-725
19. González-Sarrías A, Larrosa M, Tomás-Barberán FA, Dolara P, Espín JC (2010) NF-kappaB-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts. Br J Nutr 104:503-512
20. Verzelloni E, Pellacani C, Tagliazucchi D, Tagliaferri S, Calani L, Costa LG, Brighenti F, Borges G, Crozier A, Conte A, Del Rio D (2011) Antiglycative and neuroprotective activity of colon-derived polyphenol catabolites. Mol Nutr Food Res 55:S35-S43
21. Giménez-Bastida JA, Larrosa M, González-Sarrías A, Tomás-Barberán F, Espín JC, García-Conesa MT (2012) Intestinal ellagitannin metabolites ameliorate cytokine-induced inflammation and associated molecular markers in human colon fibroblasts. J Agric Food Chem 60:8866-8876
22. Dell'agli M, Galli GV, Bulgari M, Basilico N, Romeo S, Bhattacharya D, Taramelli D, Bosisio E (2010) Ellagitannins of the fruit rind of pomegranate (Punica granatum) antagonize in vitro the host inflammatory response mechanisms involved in the onset of malaria. Malar J 9:208
23. Giménez-Bastida JA, Truchado P, Larrosa M, Espín JC, Tomás-Barberán FA, Allende A, García-Conesa MT (2012) Urolithins, ellagitannin metabolites produced by colon microbiota, inhibit quorum sensing in Yersinia enterocolitica: phenotypic response and associated molecular changes. Food Chem 132:1465-1474
24. Larrosa M, González-Sarrías A, García-Conesa MT, Tomás-Barberán FA, Espín JC (2006) Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J Agric Food Chem 54:1611-1620
25. Giménez-Bastida JA, González-Sarrías A, Larrosa M, Tomás-Barberán F, Espín JC, García-Conesa MT (2012) Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-α-induced inflammation and associated molecular markers in human aortic endothelial cells. Mol Nutr Food Res 56:784-796
26. González-Sarrías A, Miguel V, Merino G, Lucas R, Morales JC, Tomás-Barberán F, Álvarez AI, Espín JC (2013) The gut microbiota ellagic acid-derived metabolite urolithin A, and its sulfate conjugate, are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP). J Agric Food Chem 61:4352-4359
27. Huang Y, Sadée W (2006) Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 239:168-182
28. Morgan DM (1998) Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol 79:179-183
29. Zhang L, Zuo Z, Lin G (2007) Intestinal and hepatic glucuronidation of flavonoids. Mol Pharmacol 4:833-845
30. Shen SC, Chen YC, Hsu FL, Lee WR (2003) Differential apoptosis-inducing effect of quercetin and its glycosides in human promyeloleukemic HL-60 cells by alternative activation of the caspase 3 cascade. J Cell Biochem 89:1044-1055
31. Aires V, Limagne E, Cotte AK, Latruffe N, Ghiringhelli F, Delmas D (2013) Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res 57:1170-1181
32. Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ, Patterson AV, Stratford IJ, Morrow CS, Townsend AJ, Jounaidi Y, Chen CS, Su T, Lu H, Schwartz PS, Waxman DJ (2005) Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33:1083-1096
33. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27-42
34. Glavinas H, Kis E, Pál A, Kovács R, Jani M, Vági E, Molnár E, Bánsághi S, Kele Z, Janáky T, Báthori G, von Richter O, Koomen GJ, Krajcsi P (2007) ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug Metab Dispos 35:1533-1542
35. Fukuda Y, Schuetz JD (2012) ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol 83:1073-1083
36. Espín JC, Larrosa M, García-Conesa MT, Tomás- Barberán, FA (2013) Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far. Evid Based Complement Alternat Med 270418
37. Stolarczyk M, Piwowarski JP, Granica S, Stefańska J, Naruszewicz M, Kiss AK (2013) Extracts from Epilobium sp. herbs, their components and gut microbiota metabolites of Epilobium Ellagitannins, Urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion. Phytother Res. doi: 10.1002/ptr.4941
38. Larrosa M, Tomás-Barberán FA, Espín JC (2004) The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr 43:275-284
39. Larrosa M, Tomás-Barberán FA, Espín JC (2006) The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem 17:611-625
40. Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, Smyth JF, Jodrell DI (2003) Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 63:8443-8450
41. Gagnon JF, Bernard O, Villeneuve L, Têtu B, Guillemette C (2006) Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 12:1850-1858
42. Zhang H, Tolonen A, Rousu T, Hirvonen J, Finel M (2011) Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells. Drug Metab Dispos 39:456-464
43. Sugatani J, Osabe M, Kurosawa M, Kitamura N, Ikari A, Miwa M (2010) Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression. Drug Metab Dispos 38:177-186
44. Álvarez AI, Vallejo F, Barrera B, Merino G, Prieto JG, Tomás-Barberán FA, Espín JC (2011) Bioavailability of the glucuronide and sulfate conjugates of genistein and daidzein in breast cancer resistance protein 1 knockout mice. Drug Metab Dispos 39:2008-2012